Itraconazole therapy in lymphangitic and cutaneous sporotrichosis.
Itraconazole therapy in lymphangitic and cutaneous sporotrichosis.
复制标题
伊曲康唑治疗淋巴管炎和皮肤孢子丝菌病。
DOI：
10.1001/archderm.1986.01660160069021
复制
发表时间：
1986
影响因子：
--
通讯作者：
R. Gutierrez
中科院分区：
文献类型：
--
作者：
Á. Restrepo;J. Robledo;I. Gómez;A. M. Tabares;R. Gutierrez
用伊曲康唑治疗皮肤和淋巴管炎孢子丝菌病17例，伊曲康唑是一种新的口服可吸收的唑衍生物。这种每天100毫克的药物被证明对所有病例都有效。治疗90至180天后，皮损消失，培养结果为阴性。没有重大的副作用。17例患者中有14例进行了平均115天的治疗后评估，结果显示没有复发。目的用评分系统对治疗前的异常进行评估，结果显示治疗前的异常在不同时间完全消失，即35.3%(6/17)的患者在治疗后90天恢复正常，45.4%(5/11)的患者在治疗后120天恢复，83.3%(5/6)的患者在治疗后150天恢复。因此，在孢子丝菌病的治疗中，伊曲康唑治疗是一种适当的替代碘治疗。
Itraconazole, a new orally absorbable azole derivative, was used for the treatment of 17 patients with cutaneous and lymphangitic sporotrichosis. The drug, administered at a dose of 100 mg/day, proved to be effective in all cases. Lesions disappeared and cultures became negative after 90 to 180 days of therapy. There were no major side effects. Posttherapy evaluations, done in 14 of 17 cases for an average of 115 days, revealed no relapses. Objective evaluation of the treatment by means of a scoring system indicated complete resolution of the pretherapy abnormalities at varying periods; thus, 35.3% (six of 17) of the patients had recovered by 90 days, 45.4% (five of 11) by 120 days, and 83.3% (five of six) by 150 days of therapy. Consequently, therapy with itraconazole is an adequate alternative to iodide treatment in sporotrichosis.